{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"SGNB6A-001","nct_id":"NCT04389632","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sgnb6a-001-nct04389632. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"sigvotatug vedotin monotherapy","label":"Part A: Dose escalation","type":"EXPERIMENTAL"},{"description":"sigvotatug vedotin monotherapy","label":"Part B: Dose expansion","type":"EXPERIMENTAL"},{"description":"sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)","label":"Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC","type":"EXPERIMENTAL"},{"description":"sigvotatug vedotin + pembrolizumab +/- (carboplatin)","label":"Part D: sigvotatug vedotin combination therapy in 1L NSCLC","type":"EXPERIMENTAL"},{"description":"sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)","label":"Part D: sigvotatug vedotin combination therapy in 1L HNSCC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-03-22","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small Cell Lung","Squamous Cell Carcinoma of Head and Neck","HER2 Negative Breast Neoplasms","Esophageal Squamous Cell Carcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Ovarian Neoplasms","Cutaneous Squamous Cell Cancer","Exocrine Pancreatic Adenocarcinoma","Urinary Bladder Neoplasms","Uterine Cervical Neoplasms","Stomach Neoplasms"],"enrollment":{"count":1006,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"sigvotatug vedotin","otherNames":["SGN-B6A","PF-08046047"],"type":"DRUG"},{"name":"pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"cisplatin","otherNames":[],"type":"DRUG"},{"name":"carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-06","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-06-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with adverse events (AEs)","timeFrame":"Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years"},{"measure":"Number of patients with laboratory abnormalities","timeFrame":"Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years"},{"measure":"Number of participants with dose-limiting toxicities (DLTs)","timeFrame":"Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years"}],"references":[{"citation":"Lyon RP, Jonas M, Frantz C, Trueblood ES, Yumul R, Westendorf L, Hale CJ, Stilwell JL, Yeddula N, Snead KM, Kumar V, Patilea-Vrana GI, Klussman K, Ryan MC. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453. doi: 10.1158/1535-7163.MCT-22-0817.","pmid":"37619980","type":"DERIVED"}],"start_date":{"date":"2020-06-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04389632"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sgnb6a-001-nct04389632"}